Generalized Anxiety Disorder - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: G03206B2800CEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Generalized Anxiety Disorder - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Generalized Anxiety Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Generalized Anxiety Disorder Understanding

The DelveInsight Generalized Anxiety Disorder epidemiology report gives a thorough understanding of the Generalized Anxiety Disorder by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Generalized Anxiety Disorder in the US, Europe, and Japan. The report covers the detailed information of the Generalized Anxiety Disorder epidemiology scenario in seven major countries (US, EU5, and Japan).

Generalized Anxiety Disorder Epidemiology Perspective by DelveInsight

The Generalized Anxiety Disorder epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Generalized Anxiety Disorder epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Generalized Anxiety Disorder epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Generalized Anxiety Disorder Detailed Epidemiology Segmentation

The Generalized Anxiety Disorder epidemiology covered in the report provides historical as well as forecasted Generalized Anxiety Disorder epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Generalized Anxiety Disorder report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Generalized Anxiety Disorder report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Generalized Anxiety Disorder Epidemiology Report and Model provide an overview of the global trends of Generalized Anxiety Disorder in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Generalized Anxiety Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Generalized Anxiety Disorder
• The report provides the segmentation of the Generalized Anxiety Disorder epidemiology

Report Highlights

• 11-year Forecast of Generalized Anxiety Disorder epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Generalized Anxiety Disorder
• Cases of Generalized Anxiety Disorder by Mutation Types
• Generalized Anxiety Disorder Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Generalized Anxiety Disorder?
• What are the key findings pertaining to the Generalized Anxiety Disorder epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Generalized Anxiety Disorder across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Generalized Anxiety Disorder?
• What are the currently available treatments of Generalized Anxiety Disorder?

Reasons to buy

The Generalized Anxiety Disorder Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Generalized Anxiety Disorder market
• Quantify patient populations in the global Generalized Anxiety Disorder market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Generalized Anxiety Disorder therapeutics in each of the markets covered
• Understand the magnitude of Generalized Anxiety Disorder population by its epidemiology
• The Generalized Anxiety Disorder Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF GENERALIZED ANXIETY DISORDER

3. GENERALIZED ANXIETY DISORDER: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Generalized Anxiety Disorder Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Generalized Anxiety Disorder Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Generalized Anxiety Disorder Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Generalized Anxiety Disorder Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Generalized Anxiety Disorder Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Generalized Anxiety Disorder Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Generalized Anxiety Disorder Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Generalized Anxiety Disorder Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Generalized Anxiety Disorder Treatment and Management
6.2. Generalized Anxiety Disorder Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Generalized Anxiety Disorder Epidemiology in 7MM (2019-2032)
Table 2: Generalized Anxiety Disorder Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Generalized Anxiety Disorder Epidemiology in the United States (2019-2032)
Table 4: Generalized Anxiety Disorder Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Generalized Anxiety Disorder Epidemiology in Germany (2019-2032)
Table 6: Generalized Anxiety Disorder Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Generalized Anxiety Disorder Epidemiology in France (2019-2032)
Table 8: Generalized Anxiety Disorder Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Generalized Anxiety Disorder Epidemiology in Italy (2019-2032)
Table 10: Generalized Anxiety Disorder Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Generalized Anxiety Disorder Epidemiology in Spain (2019-2032)
Table 12: Generalized Anxiety Disorder Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Generalized Anxiety Disorder Epidemiology in the United Kingdom (2019-2032)
Table 14: Generalized Anxiety Disorder Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Generalized Anxiety Disorder Epidemiology in Japan (2019-2032)
Table 16: Generalized Anxiety Disorder Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Generalized Anxiety Disorder Epidemiology in 7MM (2019-2032)
Figure 2 Generalized Anxiety Disorder Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Generalized Anxiety Disorder Epidemiology in the United States (2019-2032)
Figure 4 Generalized Anxiety Disorder Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Generalized Anxiety Disorder Epidemiology in Germany (2019-2032)
Figure 6 Generalized Anxiety Disorder Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Generalized Anxiety Disorder Epidemiology in France (2019-2032)
Figure 8 Generalized Anxiety Disorder Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Generalized Anxiety Disorder Epidemiology in Italy (2019-2032)
Figure 10 Generalized Anxiety Disorder Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Generalized Anxiety Disorder Epidemiology in Spain (2019-2032)
Figure 12 Generalized Anxiety Disorder Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Generalized Anxiety Disorder Epidemiology in the United Kingdom (2019-2032)
Figure 14 Generalized Anxiety Disorder Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Generalized Anxiety Disorder Epidemiology in Japan (2019-2032)
Figure 16 Generalized Anxiety Disorder Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report